The White House will announce a drug pricing deal on April 23 with Regeneron, the final holdout among large pharmaceutical companies to sign most favored nation pricing deals with the Trump administration, according to a source familiar with the matter.
Regeneron will become the 17th large pharmaceutical company to sign a drug pricing agreement after receiving letters from President Donald Trump in July.
A Regeneron representative did not immediately respond to questions about the deal, which was first reported by the news outlet NOTUS. Regeneron spokesperson Alexandra Bowie on April 3 told USA TODAY the company expected to announce a most favored nation agreement “in the near future.”
Trump has made most favored nation deals a centerpiece of his administration’s effort to lower drug prices for consumers.
The administration previously announced deals with 16 of 17 major drug manufacturers that it sent letters to in 2025 seeking price concessions on brand-name drugs.
While touting these deals as a boon for consumers during oval office announcements, the Trump administration hasn’t publicly released terms of the voluntary agreements. The administration’s drug-pricing website, TrumpRx, listed prices of more than five dozen brand-name fertility, insulin, weight loss and other medications as of this month. The website directs cash-paying consumers to drug manufacturers websites or coupons that can be used at pharmacies. The site does not process insurance claims.
The Trump administration announced plans to assess 100% tariffs on imported brand-name drugs as part of a sweeping April 2 order.
Drugmakers that agree to move some drug production to the United States and agree to most favored nation pricing deals would pay no tariffs under the order. If drug companies only move production to the U.S., they would pay a 20% tariff.
